PT3148510T - Composição farmacêutica líquida - Google Patents

Composição farmacêutica líquida

Info

Publication number
PT3148510T
PT3148510T PT157249749T PT15724974T PT3148510T PT 3148510 T PT3148510 T PT 3148510T PT 157249749 T PT157249749 T PT 157249749T PT 15724974 T PT15724974 T PT 15724974T PT 3148510 T PT3148510 T PT 3148510T
Authority
PT
Portugal
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
liquid
composition
pharmaceutical
Prior art date
Application number
PT157249749T
Other languages
English (en)
Portuguese (pt)
Inventor
Del Rio Alessandra
Rinaldi Gianluca
FRATARCANGELI Silvia
Original Assignee
Fresenius Kabi Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50774705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3148510(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fresenius Kabi Deutschland Gmbh filed Critical Fresenius Kabi Deutschland Gmbh
Publication of PT3148510T publication Critical patent/PT3148510T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT157249749T 2014-05-23 2015-05-15 Composição farmacêutica líquida PT3148510T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14169754.0A EP2946766B1 (en) 2014-05-23 2014-05-23 Liquid pharmaceutical composition

Publications (1)

Publication Number Publication Date
PT3148510T true PT3148510T (pt) 2018-09-28

Family

ID=50774705

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157249749T PT3148510T (pt) 2014-05-23 2015-05-15 Composição farmacêutica líquida

Country Status (21)

Country Link
US (5) US10493152B2 (enExample)
EP (6) EP2946766B1 (enExample)
JP (3) JP2017516847A (enExample)
CN (2) CN106659781A (enExample)
AU (4) AU2015263246B2 (enExample)
CA (2) CA2947487C (enExample)
CY (1) CY1120488T1 (enExample)
DE (2) DE23189888T1 (enExample)
DK (3) DK3148510T3 (enExample)
ES (5) ES2572919T3 (enExample)
HK (1) HK1257026A1 (enExample)
HR (1) HRP20181226T1 (enExample)
HU (1) HUE040097T2 (enExample)
IL (1) IL249117B2 (enExample)
LT (1) LT3148510T (enExample)
PL (1) PL3148510T3 (enExample)
PT (1) PT3148510T (enExample)
RS (1) RS57772B1 (enExample)
SI (1) SI3148510T1 (enExample)
SM (1) SMT201800413T1 (enExample)
WO (1) WO2015177058A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
EP2946765B1 (en) 2014-05-23 2016-08-31 Ares Trading S.A. Liquid pharmaceutical composition
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
ES2938608T3 (es) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
US12491234B2 (en) * 2018-03-29 2025-12-09 Airway Therapeutics, Inc. Methods and compositions comprising surfactant protein D (SP-D)
IL277469B2 (en) 2018-03-29 2024-11-01 Airway Therapeutics Inc Systems and methods for characterizing surfactant protein d (sp-d) oligomers
WO2020138517A1 (ko) * 2018-12-24 2020-07-02 삼성바이오에피스 주식회사 항-TNFα 항체를 포함하는 약제학적 조성물
TW202042840A (zh) * 2019-01-11 2020-12-01 南韓商三星Ｂｉｏｅｐｉｓ股份有限公司 包含抗體的醫藥組成物、包含其的裝置、及其用途
CN113727730A (zh) * 2019-03-18 2021-11-30 阿尔沃科技Hf公司 高浓度TNFα抗体的含水制剂
CN115429751B (zh) * 2022-09-21 2023-11-17 景泽生物医药(合肥)股份有限公司 一种人重组卵泡刺激素注射剂及其制备方法
AU2024325145A1 (en) * 2023-08-15 2026-02-05 Amgen Inc. Acidic buffered intravenous solution stabilizers for use in methods of treatment

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6388197A (ja) 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6258562B1 (en) 1996-02-09 2001-07-10 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5900404A (en) 1997-08-15 1999-05-04 Amgen Inc. Chemical modification of proteins to improve biocompatibility and bioactivity
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
PL1610820T5 (pl) * 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
US8008447B2 (en) * 2004-07-23 2011-08-30 Genentech, Inc. Crystallization of antibody or fragment thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2006249083A (ja) 2005-03-08 2006-09-21 Pharmacia & Upjohn Co Llc 抗ｍ−ｃｓｆ抗体組成物
EP3260465A1 (en) 2005-06-07 2017-12-27 ESBATech, an Alcon Biomedical Research Unit LLC Stable and soluble antibodies inhibiting tnf-alpha
KR20210049186A (ko) 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
US9393304B2 (en) 2008-10-29 2016-07-19 Ablynx N.V. Formulations of single domain antigen binding molecules
KR20110097772A (ko) 2008-11-17 2011-08-31 제넨테크, 인크. 생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제
CN102458469B (zh) 2009-05-04 2014-12-24 艾伯维生物技术有限公司 人抗TNF-α抗体的稳定高蛋白质浓度制剂
SI3409289T1 (sl) * 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
CN105521491B (zh) 2010-03-01 2020-03-24 西托戴恩有限公司 浓缩蛋白制剂及其用途
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
PL2550018T3 (pl) 2010-03-22 2019-08-30 F.Hoffmann-La Roche Ag Kompozycje i sposoby użyteczne do stabilizowania preparatów zawierających białko
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
AU2011325974B2 (en) 2010-11-11 2016-10-27 Abbvie Biotechnology Ltd. Improved high concentration anti-TNFalpha antibody liquid formulations
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
EA026226B1 (ru) 2011-07-01 2017-03-31 Байоджен Айдек Ма Инк. Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
EP3412310B1 (en) * 2012-03-07 2022-09-07 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
EP2863951A1 (en) * 2012-06-12 2015-04-29 Boehringer Ingelheim International GmbH Pharmaceutical formulation for a therapeutic antibody
PE20150964A1 (es) * 2012-09-07 2015-07-25 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
HK1211840A1 (en) 2012-10-25 2016-06-03 米迪缪尼有限公司 Stable, low viscosity antibody formulation
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
AR093297A1 (es) * 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
HK1213204A1 (zh) 2012-11-01 2016-06-30 Abbvie Inc. 穩定雙重可變結構域免疫球蛋白製劑
CN104707146B (zh) 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
IN2014MU00610A (enExample) 2014-02-21 2015-09-25 Tata Motors Ltd
IN2014MU01248A (enExample) 2014-04-02 2015-10-09 Intas Pharmaceuticals Ltd
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
EP2946765B1 (en) 2014-05-23 2016-08-31 Ares Trading S.A. Liquid pharmaceutical composition
US11285210B2 (en) * 2016-02-03 2022-03-29 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
EP3569224B1 (en) 2017-01-11 2022-12-14 Celltrion Inc. Stable liquid formula
CA3169901A1 (en) 2020-03-13 2021-09-16 Mi Gyeong Kim Pharmaceutical liquid composition having increased stability

Also Published As

Publication number Publication date
EP4249060A2 (en) 2023-09-27
LT3148510T (lt) 2018-10-10
SMT201800413T1 (it) 2018-11-09
ES2955316T3 (es) 2023-11-30
AU2018222887B2 (en) 2020-02-27
US20230061801A1 (en) 2023-03-02
ES2683194T3 (es) 2018-09-25
EP3148510A1 (en) 2017-04-05
HK1257026A1 (zh) 2019-10-11
CN108785670A (zh) 2018-11-13
US11752208B2 (en) 2023-09-12
CA2947487C (en) 2019-09-24
US11752209B2 (en) 2023-09-12
US20230338527A1 (en) 2023-10-26
AU2015263246A1 (en) 2016-11-17
EP2946766B1 (en) 2016-03-02
EP3659582B1 (en) 2023-08-16
JP6962984B2 (ja) 2021-11-05
JP2017516847A (ja) 2017-06-22
CA3050875A1 (en) 2015-11-26
US20170189527A1 (en) 2017-07-06
EP3148510B1 (en) 2018-06-27
JP2020033361A (ja) 2020-03-05
US20200085948A1 (en) 2020-03-19
IL249117B1 (en) 2024-07-01
CN106659781A (zh) 2017-05-10
EP4585614A2 (en) 2025-07-16
ES2928738T3 (es) 2022-11-22
DK201800071U1 (da) 2018-12-05
US12109267B2 (en) 2024-10-08
AU2018222887A1 (en) 2018-09-13
JP2022003091A (ja) 2022-01-11
AU2015263246B2 (en) 2018-06-21
US10493152B2 (en) 2019-12-03
EP4249060A3 (en) 2024-01-03
DK201800070Y8 (da) 2019-07-09
CA2947487A1 (en) 2015-11-26
EP3403646B1 (en) 2022-09-28
EP4585614A3 (en) 2025-10-29
AU2020201090B2 (en) 2022-03-10
RS57772B1 (sr) 2018-12-31
AU2022203863A1 (en) 2022-06-23
DK201800070U1 (da) 2018-09-18
IL249117B2 (en) 2024-11-01
PL3148510T3 (pl) 2018-11-30
US10772961B2 (en) 2020-09-15
DE25179059T1 (de) 2025-08-28
HUE040097T2 (hu) 2019-02-28
AU2020201090A1 (en) 2020-03-05
DE23189888T1 (de) 2024-03-21
HRP20181226T1 (hr) 2018-10-19
DK201800070Y4 (da) 2018-12-13
DK201800071Y4 (da) 2018-12-13
DK3148510T3 (en) 2018-07-16
EP3403646A1 (en) 2018-11-21
ES3053508T2 (en) 2026-01-22
US20210023215A1 (en) 2021-01-28
WO2015177058A1 (en) 2015-11-26
SI3148510T1 (sl) 2018-10-30
ES2572919T3 (es) 2016-06-03
EP3659582A1 (en) 2020-06-03
IL249117A0 (en) 2017-01-31
EP2946766A1 (en) 2015-11-25
CY1120488T1 (el) 2019-07-10

Similar Documents

Publication Publication Date Title
IL282481A (en) A liquid pharmaceutical preparation
ZA201901590B (en) Liquid pharmaceutical composition
IL277241A (en) A liquid pharmaceutical preparation
ZA201901736B (en) Liquid pharmaceutical composition
GB201409471D0 (en) Pharmaceutical composition
IL249117A0 (en) A liquid pharmaceutical preparation
SG11201605366QA (en) Pharmaceutical composition containing pyridylaminoacetic acidcompound
GB201409488D0 (en) Pharmaceutical composition
EP3120835A4 (en) Liquid pharmaceutical composition
GB201409485D0 (en) Pharmaceutical composition
LT3206666T (lt) Skysta farmacinė kompozicija, apimanti pemetreksedą
LT3089740T (lt) Farmacinė kompozicija
SG10201504332VA (en) Pharmaceutical Composition
IL253572A0 (en) A liquid pharmaceutical preparation